ClinicalTrials.gg
RecruitingNCT05166343PRIMEUpdated Mar 11, 2025

POHCA Resuscitation: Evaluation of IM Epinephrine

A Phase 2/3 interventional study of Epinephrine Injection in Pediatric Out-of-Hospital Cardiac Arrest, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 1 Day to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Phase 2/3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
1 Day to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Heart Arrest with a site in Canada — 10 open to participants now, 13 under way, 1 of them phase 3. Heart Arrest · Canada.

Planned enrollment
22nd of 46
284 · median 246
Started
2024
the only one that year
Phase 2/3
Only one
of the 65
Primary completion
2028-01
later than 6 of 12 live
Registered
54th of 65
by date

Among the 65 studies in Heart Arrest with a site in Canada, this one is the 22nd largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2/3, reaches primary completion later than 6 of the 12 other live ones, and was the 54th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

10 of the 65 studies in Heart Arrest with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 1 Day to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Heart Arrest with a site in Canada, or all of them as a file.
02

Study summary

This is a pragmatic, two-arm, open-label, prospective stepped-wedge cluster quasi randomized control trial (SW-CRCT) looking to evaluate early intramuscular (IM) epinephrine in the management of pediatric out-of-hospital cardiac arrest (POHCA).

Read the detailed description

IM epinephrine may provide a more efficient means of administering the initial epinephrine dose (versus IV/IO administration) to a child experiencing pediatric out of hospital cardiac arrest (POHCA) with no greater risk of harm. In so doing, this may improve the short- and long-term outcomes of these patients. There is an abundance of literature detailing the risk/benefit profile of IM epinephrine use in anaphylaxis; however, there is no human data on this topic as it relates to cardiac arrest. Important knowledge gaps include whether the use of IM epinephrine via autoinjector and/or pre-filled syringe leads to faster administration of the initial doses of epinephrine without delaying time to definitive epinephrine (via IV/IO) and the impact on time to initial and sustained return of spontaneous circulation (ROSC). This trial will be the first to examine the role of IM epinephrine via autoinjector/pre-filled syringe in POHCA.

03

Conditions studied

  • Pediatric Out-of-Hospital Cardiac Arrest

Browse trials for

Keywords

  • cardiac arrest
  • IM Epinephrine
  • standard of care
  • pediatric
  • resuscitation
04

Who can participate

Ages eligible
1 Day to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 1 day to and including 17 years experiencing an out-of-hospital cardiac arrest (OHCA)
  • Must be receiving at least 1 minute of CPR by trained first responders (police, fire, or paramedic services)

Exclusion criteria

Exclusion Criteria:

  • Children who experience OHCA due to an obvious traumatic event.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
284 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    All POHCA events will be handled per standard of care of epinephrine administration via intravenous or intraosseous (IV/IO) based on patient estimated weight.

  • Other
    Intramuscular Epinephrine Dose

    POHCA events will be handled per standard of care, however, first dose epinephrine administration will be via intramuscular (IM) autoinjector and/or pre-filled syringes. Dosing will be dependent on weight as follows: * 3-\<5kg=0.3mg IM epinephrine * 5-\<10kg=0.5mg IM epinephrine * 10-\<20kg=1.0mg IM epinephrine * 20-\<30kg=2.0mg IM epinephrine * 30kg=3.0mg IM epinephrine

    Drug: Epinephrine Injection

Interventions

  • DrugEpinephrineStudies of EpinephrineEpinephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).

06

What researchers measure

Primary outcomes

  1. Time to initial return of spontaneous circulation (ROSC)

    The primary outcome will be the time to initial ROSC. The investigator will compare time to initial ROSC between the standard of care and intervention periods.

    Time frame: At time of event

Secondary outcomes

  1. Return of spontaneous circulation

    Whether return of spontaneous circulation is achieved or not

    Time frame: At time of event

  2. Time to sustained ROSC

    Time to sustained ROSC will be calculated from the time that paramedics arrive on scene to the time that sustained ROSC, defined as chest compressions not required for 20 minutes with persistent signs of circulation, is achieved.

    Time frame: At time of event

  3. Survival

    Survival to emergency department transfer to pediatric critical care unit (PCCU), if applicable: admitted to PCCU from external ED

    Time frame: From time of event to ED admission

  4. Survival - comparison between both arms

    Survival to hospital admission will be compared between standard of care and intervention periods

    Time frame: From time of event to hospital admission

  5. PCCU/Hospital length of stay

    PCCU and hospital length of stay will be calculated from time of admission to the PCCU/hospital and time to discharge from PCCU/hospital, if applicable, between standard of care and intervention periods

    Time frame: From time of hospital/PCCU admission to discharge, up to 1 year

  6. Survival to hospital discharge

    Survival to hospital discharge will be compared between standard of care and intervention periods

    Time frame: Dependent on course of hospital stay, up to 1 year

  7. Post POHCA survival

    Survival at 6 months and 12 months post-POHCA will be compared between standard of care and intervention periods

    Time frame: Dependent on survival at 6 and 12 month period post POHCA event

  8. Neurological status

    The investigator will compare PCPC scores at discharge, 6- and 12-months post-POHCA between the standard of care and intervention periods

    Time frame: From time of discharge and 6 and 12 months post POHCA event

  9. Life Impact and Pediatric Quality of Life assessments

    Life Impact assessment between 6 and 12 months: the investigator will use the Pediatric Quality of Life (PEDSQoL, Pediatrics Quality of Life) assessment tool at 6- and 12-months post-POHCA in all survivors and compare between standard of care and intervention periods. The score ranges from 0-100, with higher scores indicating better outcome.

    Time frame: 6 and 12 months post POHCA event

  10. Life Impact and Pediatric Quality of Life assessments

    Life Impact assessment between 6 and 12 months: the investigator will use the Daily Activities Scale at 6- and 12-months post-POHCA in all survivors and compare between standard of care and intervention periods. This scale is a subscore of the PEDSQoL tool with scores ranging from 0-100, with higher scores indicating better outcome.

    Time frame: 6 and 12 months post POHCA event

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital - London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
    Recruiting
    • Janice Tijssen, MD MSc · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jan 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 21, 2021
StartActual
Jan 8, 2024
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05166343
Responsible party
Janice Tijssen (MD MSc, Interim Director, Paediatric Critical Care, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Dec 21, 2021
Start date
Jan 8, 2024
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Mar 11, 2025

Study contacts

Maysaa Assaf
Contact
maysaa.assaf@lhsc.on.ca
519-685-8500 ext. 75548
Janice Tijssen, MD MSc
principal investigator · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epinephrine

Start the discussion